# US 2021/0330862 A1 · Bioresorbable biological matrix for repairing bone tissue defects and method for the production thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330862 A1
- Document ID: US20210330862A1
- Status: Published application
- Kind: A1
- Application number: 16/607,729
- Filed: 2017-12-04
- Published: 2021-10-28
- Earliest claimed: 2017-03-17
- Assignees: Limited Liability Company "Matriflex" [Ru/Ru]
- Applicants: Limited Liability Company "Matriflex" [Ru/Ru]
- Inventors: Alexey Vladimirovich VEREMEEV; Anton Gennadievich KUTIKHIN; Vladimir Georgievich NESTERENKO; Roman Nikolaevich BOLGARIN
- Web page: https://patentgrep.com/patent/US20210330862A1

## CPC

- A61L 27/365: {Bones}
- A61L 27/3687: {characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents}
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A61L 27/12: Phosphorus-containing materials, e.g. apatite
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/222: {Gelatin}
- A61L 27/26: Mixtures of macromolecular compounds
- A61L 27/3608: {Bone, e.g. demineralised bone matrix [DBM], bone powder}
- A61L 27/3616: {Blood, e.g. platelet-rich plasma}
- A61L 27/3691: {characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation}
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/58: Materials at least partially resorbable by the body
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61L 2103/05: Living organisms or biological materials
- A61L 2300/402: Anaestetics, analgesics, e.g. lidocaine
- A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents
- A61L 2300/406: Antibiotics
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- A61L 2430/40: Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to medical biotechnology, medicine, traumatology, orthopedics, dentistry, and orthodontics. A method is proposed for producing a biological matrix intended for the repairing of bone tissue defects; said method may include a plurality of consecutive stages, such as pre-treating biological material, coarse filtering and fractionating, fine filtering and extracting, delipidizing, fermenting, demineralizing, and sterilizing in supercritical fluid. The resulting bioresorbable biological matrix is characterized by increased osteo- and biointegration, an optimal biodegradation rate, high biocompatibility, an absence of recipient immunoreactivity, high osteoconduction capacity, and pronounced osteogenic potential in osteosynthesis and bone grafting. The matrix consists of ossein, hydroxyapatite and/or calcium phosphate, wherein the ossein is in native unreduced form with its three-dimensional structure completely intact, the hydroxyapatite and calcium phosphate are in native amorphous form, and the matrix itself, from which cellular debris, foreign lipids, nucleic acids, and immunogens have been removed, contains residual amounts of bone morphogenetic proteins and is impregnated with vesicular phosphatidylcholine and/or cholesterol containing gelatin (hydrolyzed collagen), and/or bone atelocollagen, and/or poly-(ε-caprolactone) and additionally containing biologically active substances (including bioactive peptides and growth factors).

## Claims

### Claim 1

A method for producing a bioresorbable biological matrix for replacing bone defects from a xenogenic or allogeneic bone tissue, comprising the following successive stages:
a. preliminary processing of the xenogenic or allogeneic bone tissue, comprising one or more cycles of freezing at −20 to −80° C. and thawing at +5 to +37° C.;
b. deep cleaning and extracting of the material obtained in the previous stage, comprising treatment of this material in a solution of ionic or ionic and amphoteric detergent in a buffer solution, then, optionally, washing in a buffer solution, then further processing in a solution of non-ionic detergent, followed by extracting the material using an ultrasonic disintegrator;
c. delipidating the material obtained in the previous stage, comprising processing the material in a solution of ethanol or ethanol-chloroform or ethanol-ethyl acetate and toluene, and then processing with sodium hydroxide;
d. demineralizing the material obtained in the previous stage, comprising treating the material with a strong acid solution, followed by neutralizing with sodium hydroxide;
e. impregnating the material obtained in the previous stage with a solution containing vesicular phosphatidylcholine or cholesterol, wherein the solution further contains gelatin (hydrolyzed collagen) or bone atelocollagen or poly-(e-caprolactone).

### Claim 2 (depends on 1)

The method according to claim 1, wherein between the preliminary processing and deep cleaning stages, there is an additional stage of coarse cleaning and fractionation of the material obtained in the preliminary processing stage, in which a spongy layer is separated partially or completely from a cortical layer, and/or a diaphysis is separated partially or completely from a metaphysis and epiphysis (pineal gland), and/or a periosteal and middle layer is separated partially or completely from an endosteal layer.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the partial separation of the periosteal and middle layer from the endosteal layer is carried out to a depth of 8-10 mm.

### Claim 4 (depends on 1)

The method according to claim 1, wherein at the stage of deep cleaning and extraction, sodium dodecyl sulfate and/or 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate in a concentration of 0.1-10% are used as ionic detergent at 37-41° C.; and Triton X-100 at a concentration of 0.1-5% and/or Tween-20 at a concentration of 0.005-1% are used as non-ionic detergents at 1-8° C.

### Claim 5 (depends on 1)

The method according to claim 1, wherein between the stages of delipidation and demineralization an additional stage of fermentation of the processed material is carried out, comprising processing of the material in solutions of DNase I or trypsin.

### Claim 6 (depends on 1)

The method according to claim 1, wherein there is an additional stage of sterilization of the material obtained at the stage of demineralization between the stages of demineralization and impregnation, which includes processing of the material with a supercritical carbon dioxide.

### Claim 7 (depends on 6)

The method according to claim 6, wherein at the sterilization stage, the material is statically saturated with the supercritical carbon dioxide at 35-41° C. for 1-3 hours with a constant supply of carbon dioxide at a speed of 1.5-5 kg/h.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the material is additionally impregnated with bioactive peptides or growth factors at the stage of impregnation.

### Claim 9 (depends on 1)

The method according to claim 1, wherein at the stage of impregnation, the impregnation of the material is carried out using an ultrasonic disintegrator.

### Claim 10 (depends on 1)

A bioresorbable biological matrix for replacement of bone defects obtained by the method according to claim 1, consisting of bone collagen, hydroxyapatite and calcium phosphate, and also containing vesicular phosphatidylcholine or cholesterol, and further containing gelatin (hydrolyzed collagen), or bone atelocollagen, or poly-(ε-caprolactone), wherein the matrix is characterized by the fact that bone collagen is presented in a native form with a preserved three-dimensional structure; hydroxyapatite and calcium phosphate are presented in a native amorphous form; and the matrix itself is essentially free from cell debris, foreign lipids, nucleic acids and immunogens, has osteoconductive and osteoinductive potential, is sterile and can be presented in various forms.

### Claim at position 11

11-23. (canceled)

### Claim 24 (depends on 10)

The bioresorbable biological matrix according to claim 10, wherein the matrix additionally contains an autologous stromal-vascular fraction and/or mesenchymal stem cells added during the impregnation stage; and/or human blood plasma enriched with platelets, added during the impregnation stage; and/or autologous blood; and/or bioactive peptides and/or growth factors; and/or an antibiotic, antimycotic, antiseptic and/or anesthetic agents.
